This paper explores the issue of direct-to-consumer (DTC) advertising of prescription drugs. The viewpoints of the four major groups involved—pharmaceutical manufacturers, physicians, regulators and consumers—are discussed, the legal questions such advertising raises are examined and the costs and benefits of it are reviewed. Finally, some recommendations are developed to assist the two groups most actively involved: manufacturers and regulators.
Get full access to this article
View all access options for this article.
References
1.
AlexanderCharles P. (1985), “Robins Runs for Shelter,”Time, 126, 9 (September 2), 32–33.
2.
BainJoe S. (1956), Barriers to New Competition, Cambridge, Massachusetts: Harvard University Press.
3.
BeauchampT.L., and ChildressJ.F. (1979), Principles of Biomedical Ethics, New York: Oxford University Press.
4.
BenhamL. (1972), “The Effect of Advertising on the Price of Eyeglasses,”Journal of Law and Economics, 15, 337–352.
5.
BettmanJames R., PayneJohn W., and StaelinRichard (1986), “Cognitive Considerations in Designing Effective Labels for Presenting Risk Information,”Journal of Public Policy & Marketing, 5, 1–28.
6.
Borom v. Eli Lilly & Co., 83-38-COL (M.D.Ga.).
7.
BrettAllan S., and McCulloughLaurence B., [1986], “When Patients Request Specific Interventions: Defining the Limits of the Physician's Obligation,”New England Journal of Medicine, 315, 21 (November 20), 1347–1351.
8.
BucNancy L., Esq. (1982), “Current Regulatory Issues in Marketing Prescription Drugs, Comparative Claims and Advertising to Consumers,”Food Drug Cosmetic Law Journal, 37, 402–408.
9.
Business Week (1982), “Lilly feels the pain of yanking Oraflex,” (August 23), 29–30.
10.
Business Week (1984), “Unsafe Products: The Great Debate Over Blame and Punishment,” (April 30), 96–104.
11.
CBS (1984), The CBS Consumer Model: A Study of Attitudes, Concerns, and Information Needs for Prescription Drugs and Related Illnesses, New York: CBS Television Network Sales/Marketing Services.
12.
CadyJ.F. (1976a), “An Estimate of the Price Effects of Restrictions on Drug Price Advertising,”Economic Inquiry, 14, 493–510.
13.
CadyJ.F. (1976b), Restricted Advertising and Competition: The Case of Retail Drugs, Washington: American Enterprise Institute of Public Policy Research.
14.
Chemical Marketing Reporter (1982), “Lilly's ‘Oraflex’ Faces Ban: Consumer Groups Plan Suit,”222 (August 2), 18.
15.
CobbB. (1958), “Why Do People Detour to Quacks?” in JacoE.B., ed., Patients, Physicians, and Illness, New York: Free Press.
16.
CohenEric P. (1988a), “Direct-to-the-Public Advertisement of Prescription Drugs,”New England Journal of Medicine, 318, 6 (February 11), 373–375.
17.
CohenEric P. (1988b), “Advertising of Prescription Drugs,”New England Journal of Medicine, 319, 5 (August 4), 314–15.
18.
CohenEric P. (1989), “Risk of Breaking Drug-Ad Taboo,”Wall Street Journal, (May 5), p. A15, col. 1.
19.
ColfordSteven W. (1985), “CBS Readies for Prescription-Drug Ads,”Advertising Age, 56(November 11), 12.
20.
CooperRichard M. (1986), “Drug Labeling and Products Liability: The Role of the Food and Drug Administration,”Food Drug Cosmetic Law Journal, 41, 233–240.
21.
DayGeorge S., and MontgomeryDavid B. (1983), “Diagnosing the ExperienceCurve,” Journal of Marketing, 47(Spring), 44–58.
22.
DeutschClaudia H. (1989), “The Brouhaha Over Drug Ads,”The New York Times, (May 14), p. 1F, 8F.
Drug Topics (1985), “Rx-to-Consumer Advertising Debate Starts Up Again,”129 (October), 20–21.
25.
Dun's Business Month (1982), “Lilly Counts the Cost,”120 (September), 22.
26.
FarrisPaul W., and AlbionMark S. (1980), “The Impact of Advertising on the Price of Consumer Products,”Journal of Marketing, 44(Summer), 17–35.
27.
Federal Trade Commission Act (1914), Ch. 311, 38 Stat. 717.
28.
FergusonJeffrey M., DiscenzaRichard, and MillerJohn A. (1987), “Increasing the Odds of Patient Compliance Through Prescription Warning Labels,”Journal of Health Care Marketing, 7, 1 (March), 37–46.
29.
Food and Drug Administration (1983), FDA Statement of Policy: Direct-to-Consumer Advertising of Prescription Drugs, Memorandum (September 2).
30.
Food and Drug Administration (1985), 50 Federal Register, 36,667.
31.
FordGary A., and KuehlPhilip G., (1979), “Label Warning Messages in OTC Drug Advertising: An Experimental Examination of FTC Policymaking,”Current Issues and Research in Marketing 1979, 2, 115–129.
32.
Fortune (1986), “New Headaches in Painkiller Market,” (September 15), 10.
33.
GlaserMartha (1988), “Rx Market Quietly Hit $16.5 billion in ‘87: PDS,”Drug Topics, 132(March 7), 21–24.
34.
GoreckiPaul K. (1986), “The Importance of Being First: The Case of Prescription Drugs in Canada,”International Journal of Industrial Organization, 4(December), 371–395.
35.
Grainger v. Sandoz Pharmaceuticals (1979), Docket No. 79–40075 (E.D.Mich.).
36.
GreerDouglas F. (1971), “Product Differentiation and Concentration in the Brewing Industry,”Journal of Industrial Economics, 19(July), 201–219.
37.
HechtAnnabel (1983), “Drugs That Are Rx No More,”FDA Consumer, 17, 6 (July–August), 22–27.
38.
In Re Certified Questions From the United States District Court for Eastern District of Michigan, Southern Division (1984), 358 N.W.2d 873.
39.
JamesFrank E. (1988), “Doctors Don't Tell All on Drugs’ Effectiveness,”Wall Street Journal, (May 20), B1.
40.
JohnstoneJames M. (1987), “Special Problems in Direct-to-Consumer Advertising of Prescription Drugs,”Food, Drug and Cosmetic Law Journal, 42, 315–322.
KanouseDavid E., and Hayes-RothBarbara (1980), “Cognitive Considerations in the Design of Product Warnings,” in Product Labeling and Health Risks, MorrisLouis A., MazisMichael B., and BarofskyIvan, eds., Cold Spring Harbor Laboratory.
43.
KastelerJosephine, KaneRobert L., OlsenDonnal M., and ThetfordConstance, (1976), “Issues Underlying the Prevalence of ‘Doctor Shopping’ Behavior,”Journal of Health and Social Behavior, 17(December), 328–339.
44.
KelleyBill (1986), “Zenith Labs on a New Product High,”Sales and Marketing Management, (October), 42–45.
45.
KotlerPhilip (1988), Marketing Management, Englewood Cliffs, New Jersey: Prentice Hall.
46.
KoosE.L. (1950), The Health of Regionville.New York: Columbia University Press.
47.
KoosE.L. (1955), “Metropolis: What City People Think of Their Medical Services,”American Journal of Public Health, 45, 1551.
48.
Kordel v. United States (1948) 335 U.S. 345.
49.
KriegerLisa (1983), “Prescribers’ Pens are Target of Ads for the Public,”Medical World News, 24, 2 (January 24), 59–69.
50.
KrupkaL.R., and VenerA.M. (1985), “Prescription Drug Advertising: Trends and Implications,”Social Science and Medicine, 20, 191–197.
51.
LefflerKeith B. (1981), “Persuasion or Information? The Economics of Prescription Drug Advertising,”Journal of Law and Economics, 24, 45–74.
52.
LipmanJoanne (1989a), “Small Drug Maker Breaks Taboo With Ads Targeted At Customers,”Wall Street Journal, (April 20), B1.
53.
LipmanJoanne (1989b), “Drug Firm Aims to Put the Pill on TV,”Wall Street Journal, (June 19), B6.
54.
LipmanJoanne (1989c), “Ads for the Pill Get a Gimmick: $50 Off Next Gynecologist Visit,”Wall Street Journal, (November 6) B4.
MillerRoger W. (1983b), “Would Rx Ads Make People Learn or Yearn?”, FDA Consumer, 17, 8 (October), 24–27.
61.
MorrisLouis A., and KanouseDavid E., (1981), “Consumer Reactions to the Tone of Written Drug Information,”American Journal of Hospital Pharmacy, 38(May), 667–671.
62.
MorrisLouis A. (1984), Prescription Drug Advertising to Consumers: Brief Summary Formats for Television and Magazine Advertisements, Springfield, Virginia: National Technical Information Service, PB #84–178775.
63.
MorrisLouis A., and MillsteinLloyd G. (1984), “Drug Advertising to Consumers: Effects of Formats for Magazine and Television Advertisements,”Food Drug Cosmetic Law Journal, 39, 497–503.
64.
MorrisLouis A., BrinbergDavid, and PlimptonLinda, (1984), “Prescription Drug Information for Consumers: An Experiment of Source and Format,”Current Issues and Research in Advertising 1984, 7, 65–78.
65.
MorrisLouis A., RuffnerMichael, and KlimbergRonald (1985), “Warning Disclosures for Prescription Drugs,”Journal of Advertising Research, 25(October/November), 25–32.
66.
MorrisLouis A., BrinbergDavid, KlimbergRonald, RiveraCarole, and MillsteinLloyd G., (1986a), “Miscomprehension Rates for Prescription Drug Advertisements,”Current Issues and Research in Advertising 1986, 9, 1, 93–117.
67.
MorrisLouis A., BrinbergDavid, KlimbergRonald, RiveraCarole, and MillsteinLloyd G. (1986b), “The Attitudes of Consumers Toward Direct Advertising of Prescription Drugs,”Public Health Reports, 101(January-February), 82–89.
68.
NortonSeth W. (1986), “Advertising Restrictions and Size Distribution of Firms: The Case of the U.S. Retail Drug Industry,”International Journal of Advertising, 5, 59–72.
69.
NovitchMark (1984), “Direct-to-Consumer Advertising of Prescription Drugs,”Food Drug Cosmetic Law Journal, 39, 306–311.
70.
O'BrienMark M.D. (1986), “Advertising Prescription Drugs to the Public,”New England Journal of Medicine, 314, 8 (February 20), 523.
PerriMatthew, and NelsonArthur A.Jr. (1987), “An Exploratory Analysis of Consumer Recognition of Direct-To-Consumer Advertising of Prescription Medications,”Journal of Health Care Marketing, 7, 1, 9–17.
73.
RheinReginald (1988), “What's in a Name Brand? Less and Less,”Business Week, (December 5), 172.
74.
RheinsteinPeter H. (1982), “A Head Start, a Broader Audience, and an Emphasis on Difference: The New Frontiers of Prescription Drug Promotion,”Food Drug Cosmetic Law Journal, 37, 330–335.
75.
RoterDebra L. (1977), “Patient Participation in the Patient-Provider Interaction: The Effects of Patient Question Asking on the Quality of Interaction, Satisfaction and Compliance,”Health Education Monographs5, 4 (Winter), 281–315.
76.
SchwartzTeresa Moran (1986), “Consumer Warnings for Oral Contraceptives: A New Exception to the Prescription Drug Rule,”Food Drug and Cosmetic Law Journal, 41, 241–56.
77.
ShimpTerence A., and DyerRobert F. (1979), “The Pain-Pill-Pleasure Model and Illicit Drug Con-sumption,”Journal of Consumer Research, 6(June), 36–46.
78.
ShugarGerald R. (1986), “Mixed Opinions on Direct-to-Consumer Advertising,”Medical Marketing & Media, 21, 8 (August), 36–41.
79.
SmithDorothy L. (1987), “ The High Cost of Not Complying with Prescription Drugs,”Business & Health, 4, 6 (April), 30–36.
80.
Staff Report, Subcommittee on Oversight and Investigations (1984), “Prescription Drug Advertising to Consumers,”Washington: U.S. Government Printing Office, (September).
SteinerR.L. (1978), “A Dual Stage Approach to the Effects of Brand Advertising on Competition and Price,” In Marketing and the Public Interest, CadyJohn, ed., Cambridge, Massachusetts: Marketing Science Institute.
83.
Stephens v. G.D. Searle & Company (1985), 602 F.Supp. 379.
84.
StiglerGeorge J. (1961), “The Economics ofInformation,” Journal of Political Economy, 69(June), 213–225.
TootelianDennis H., GaedekeRalph M., SchlacterJohn (1988), “Branded Versus Generic Prescription Drugs: Perceptions of Risk, Efficacy, Safety, and Value,”Journal of Health Care Marketing, 8, 3 (September), 26–9.
90.
ViscusiW. Kip, MagatWesley A., and HuberJoel (1986), “Informational Regulation of Consumer Health Risks: An Empirical Evaluation of Hazard Warnings,”Rand Journal of Economics, 17(Autumn), 351–365.
91.
WaldholzMichael (1989), “Taking the Rx out of Rx Drugs,”Wall Street Journal, (June 5), B1.
92.
Wall Street Journal (1980), “Survey Finds Eyeglasses Cost Less Where Ads Run,” (May 16), 30.
93.
Wall Street Journal (1988), “Flying Happiness Pharmaceuticals,”26, (July 26), 27.
94.
WassonChester R. (1974), Dynamic Competitive Strategy and Product Life Cycles, St. Charles, Illinois: Challenge Books.
95.
WilliamsTerrell G. (1976), “Effects of an Advertising Warning Message on Consumer Attitudes and Buying Intentions,” in Marketing: 1776–1976 and Beyond, BernhardtKenneth L., ed., Chicago: American Marketing Association, 362–367.
96.
WitcherGregory (1989), “Slow Start for Upjohn's Baldness Drug,”Wall Street Journal, (April 5), B1.
